Oncology drug report - Darzalex - Daratumumab - 2015 analysis; 2016-2021 expectations

Oncology drug report - Darzalex - Daratumumab - 2015 analysis; 2016-2021 expectations

  • December 2016 •
  • 52 pages •
  • Report ID: 4547465 •
  • Format: PDF
“Darzalex: Big threat to IMD domination of MM market” is a comprehensive drug report new monoclonal antibody approved for the indication of multiple myeloma in Nov 2015.

Darzalex is a targeted therapy drug, which falls under the mAb class of drugs. It is indicated for the treatment of second line, third line and beyond multiple myeloma. It is the first monoclo-nal antibody used for treating multiple myeloma.

The report gives basic information about the drug, covering all details from brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the drug, news about Darzalex, information on competitor drugs, litigations, number of clinical trials (by year and by phase), and so on.

The report gives an analysis of the historical quarterly sales (Q4-2015 to Q3-2016) and sales expectations (from 2016-2021). The analysis broadly indicates that the drug took off really well with cumulative sales of this USD 347 mn until date.

Details of the sales analysis section

Historical quarterly sales analysis: We have shown sales analysis on quarterly basis for the past four quarters from Q4-2015 to Q3-2016. The quarterly data is also in graphical as well as tabular format.

Expected sales analysis: The report has our expectations for Darzalex sales over 2016-2021.
We have highlighted the key reasons for our expectations. All the historical as well as ex-pected sales analysis is based on:
1. Total global sales
2. US sales
3. International sales

Other important details

Key event tracker: The report highlights key events that have taken place for Darzalex from 2007 to 2016 (along with those events expected in 2016). It gives additional information about the key events that have driven sales for the drug over this period.
Clinical trial numbers: The report provides numbers of clinical trials which have started for Darzalex in 2014, 2015 and 2016 and for different phases: phase-II, phase-II/III and phase-III. It gives insights into whether the company is still spending money for taking the drug even fur-ther for other indications or for use in combination therapies.
Competitive drugs: Additionally, all the drugs which compete/can compete with Darzalex in the multiple myeloma market are listed with their details including brand name, API, company, class of drug, therapy class and treatment preference.
Clinical studies: Efficacy results of Darzalex and its competing drugs have been provided.
Litigation: We have given details of the ongoing litigation regarding Darzalex.
News: We have listed news related to Darzalex that would impact the drug’s performance.

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.